SciFluor develops proprietary new chemical entities (NCEs) for several therapeutic fields, including ophthalmology, neurology, and fibrosis. We are building on existing drugs that have shown promise in known pathways, but could not be used due to poor chemical properties. Our core scientific team use their advanced scientific knowledge to add specific chemical groups to improve drug distribution and binding, and protect more vulnerable parts of these drugs to prevent fast degradation.

Our lead drug, SF0166, is currently being studied in two separate multi-center, randomized, Phase 1/2 trials, in patients with Diabetic Macular Edema (DME) (clinicaltrials.gov ID# NCT02914613) and in patients with neovascular (wet) age-related macular degeneration (AMD) (clinicaltrials.gov ID# NCT02914639).

SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >